thyroid cancer

The company beat the consensus Wall Street estimate on the top line and guided to 2018 revenues of between $21 million and $22 million.

The firm said genomic testing volume rose 23 percent year over year, and raised its revenue guidance for full-year 2018.

The test is designed to analyze a panel of 112 genes to help in the diagnosis of thyroid nodules with indeterminate fine-needle aspiration cytology.

The firm will begin selling its ThyGeNext thyroid cancer diagnostic tool to physicians in New York and Pennsylvania in combination with ThyraMir.

Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.

The company said proceeds will be used for working capital, and may also be used to acquire or invest in complementary businesses or technologies.

Veracyte will offer 5 million shares at $10.25 per share. It has granted underwriters an option to purchase an additional 750,000 shares.

A 19-miRNA panel showed high sensitivity and specificity for differentiating benign and malignant thyroid nodules.

Cigna began covering the company's ThyGeNext next-generation sequencing-based test for thyroid cancer risk assessment in 2017.